NIAID contracts Enanta to develop Bicyclolide antibiotic
The company will use the fund for preclinical and clinical development of its new class of bridged bicyclic antibiotics known as Bicyclolides which are said to act as
Vertex Pharmaceuticals and Genomics have agreed a four-year extension to their drug discovery partnership in a deal with a potential value exceeding $220m.